Understand the source comparison
Pe-22-28 vs Other Neurogenic Peptides: Mechanistic Comparison
Pe-22-28 TLR4 modulation → BDNF upregulation Hippocampus > SVZ > cortex 10–50 μM Preclinical only. No human trials Best for hippocampal-specific models; weaker in cortical injury Dihexa HGF/Met receptor agonism Broad. Hippocampus, cortex, striatum 1–10 μM Prec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Pe-22-28
- TLR4 modulation → BDNF upregulation
- Hippocampus > SVZ > cortex
- 10–50 μM
- Preclinical only. No human trials
- Best for hippocampal-specific models; weaker in cortical injury
- Dihexa
- HGF/Met receptor agonism
- Broad. Hippocampus, cortex, striatum
- 1–10 μM
- Preclinical + early Phase I safety data
- Stronger cortical effect; synergistic with Pe-22-28 in co-treatment
- Cerebrolysin
- Multi-peptide mixture (BDNF-like activity)
- Broad neuroprotection, modest neurogenesis
- 0.1–1.0 mg/mL
- FDA orphan drug status for stroke
- Established safety profile but less mechanistic clarity
- P21
- CNTF pathway activation
- Cortex > hippocampus
- 5–25 μM
- Preclinical only
- Cortical repair-focused; pairs well with hippocampal-selective agents
- Pe-22-28 occupies a distinct niche: it's the most hippocampal-selective of the neurogenic peptides with published efficacy data, and the TLR4 mechanism means it works best in inflammatory contexts. If your model involves traumatic brain injury, ischemia, or chronic neuroinflammation, Pe-22-28 help neurogenesis research outcomes in ways that non-immune-modulating peptides cannot replicate. For pure developmental neurogenesis studies without injury, Cerebrolysin or Dihexa may produce clearer baseline effects.